This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell Medical School, and William Matsui, the study's senior author and former executive vice dean for research at Dell Medical School; and Theialife president and CEO, Thomas Ruggia, about myopia.

02:26 Theialife

27:38 University of Texas

Theialife

Theialife is a global ophthalmology drug development company focused on advancing first-in-class therapies that aim to address major unmet needs in eye diseases.

The company’s lead asset, ND10 (7-Methylxanthine), is an oral therapy designed to slow paediatric myopia progression, for which phase 3 clinical trial planning is currently under way.

Theialife is b ...